Ernexa Therapeutics Inc. Common Stock
Veridion Score
Composite trend over time
Why is ERNA moving today?
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ERNA.
ERNA insider activity
Ernexa Therapeutics Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for ERNA.
ERNA contract awards, year to date.
Public federal awards linked to this ticker.
ERNA lobbying filings, year to date.
Registered lobbying filings matched to Ernexa Therapeutics Inc. Common Stock.